Personalized medicine driven treatments in major diseases like advanced melanoma and non-small cell lung cancer (NSCLC) offer important health benefits to genetic subgroups, but can be expensive and may induce severe side effects. Whole Genome Sequencing (WGS) simultaneously tests for all relevant genetic aberrations in tumor tissue from individual cancer patients thereby allowing immediate selection of optimal therapy. This approach is likely to improve patient survival, avoid adverse effects, and to assist in controlling health care costs by offering treatment to only those identified to benefit.
Objectives of the current proposal are therefore:
A) to expand molecular profiling of tumors to improve immune- and targeted treatment selection in patients with advanced melanoma or NSCLC, and
B) to determine the cost-effectiveness and budget impact of WGS to facilitate responsible introduction.
The project consists of 6 Work Packages:
1)Diagnostic value of WGS,
2)Treatment decisions based on WGS,
3)Prediction of long-term health benefits and harms by micro-simulation,
4)Tumor-overarching early cost-effectiveness modelling,
5)Nation-wide organization of WGS, 6)Ethical, Legal and Societal Implications (ELSI) of WGS.
The project team consists of a large nation-wide consortium embedded in the Center for Personalized Cancer Treatment (CPCT)/Hartwig Medical Foundation (HMF), covering all relevant disciplines (geneticists, pathologists, bio-informatics, cancer biologists, oncologists, health economists and ethical/legal experts). This approach will provide evidence for decision making on genetic testing for optimizing health and economic outcomes for current and future personalized cancer care.Read more
During the project duration 2016-2020 this Zenodo community is curated by the Data Steward of the project. Only project members and affiliated are able to publish outputs to this community.